SciSparc Granted Patent for its Core Technology From the Australian Patent Office
24 Octubre 2023 - 6:20AM
SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty
clinical-stage pharmaceutical company focusing on the development
of therapies to treat disorders and rare diseases of the central
nervous system, announced today that it received a notice of
acceptance for its patent application for the Combinations of
Cannabinoids and N-Acylethanolamines (the “Patent”). The Patent
aligns seamlessly with the Company's core technologies design to
enhance cannabinoids’ safety by using low dosages of active
components while maintaining their therapeutic benefits.
The Patent was granted by IP Australia, the
government agency in Australia that administers intellectual
property rights and legislation for patents.
This Patent adds to the collection of patents
previously granted in Europe, the United States and Japan,
supporting the innovation of SciSparc’s technologies.
The invention relates to compositions and
methods for potentiating therapeutic effects and/or reducing the
side-effects of selected cannabinoids initially discovered in the
cannabis plant. The Patent received protection on account of
pharmaceutical compositions consisting of cannabinoids and
N-acylethanolamines, and methods for their use in preventing and
treating a variety of cannabinoid-treated conditions of such
pharmaceutical compositions.
About SciSparc Ltd.
(Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. SciSparc’s focus is on creating and
enhancing a portfolio of technologies and assets based on
cannabinoid pharmaceuticals. With this focus, the Company is
currently engaged in the following drug development programs based
on THC and/or non-psychoactive CBD: SCI-110 for the treatment of
Tourette Syndrome, for the treatment of Alzheimer's disease and
agitation; SCI-160 for the treatment of pain; and SCI-210 for the
treatment of ASD and status epilepticus. The Company also owns a
controlling interest in a subsidiary whose business focuses on the
sale of hemp seeds oil-based products on the Amazon.com
Marketplace.
Forward-Looking Statements:
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995 and other
Federal securities laws. For example, SciSparc is using
forward-looking statements when it discusses the ability of its
core technologies to enhance cannabinoids’ safety and therapeutic
effects. Historical results of scientific research and clinical and
preclinical trials do not guarantee that the conclusions of future
research or trials will suggest identical or even similar
conclusions. Because such statements deal with future events and
are based on SciSparc's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of SciSparc could differ materially from those
described in or implied by the statements in this press release.
The forward-looking statements contained or implied in this press
release are subject to other risks and uncertainties, including
those discussed under the heading "Risk Factors" in SciSparc's
Annual Report on Form 20-F filed with the SEC on May 1, 2023,
and in subsequent filings with the U.S. Securities and Exchange
Commission. Except as otherwise required by law, SciSparc disclaims
any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether
as a result of new information, future events or circumstances or
otherwise.
Investor Contact: IR@scisparc.com Tel: +972-3-6167055
SciSparc (NASDAQ:SPRC)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
SciSparc (NASDAQ:SPRC)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024